Stock Research Report - Dr. Lal PathLabs Ltd (DLPA).
Dr. Lal path labs limited is one of the leading consumer healthcare brands in diagnostic service.
It has an integrated nationwide network where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis, and the prevention, monitoring, and treatment of disease and other health conditions. The services of DLPL are aimed at an individual patient, hospital and other healthcare providers and corporates. The catalog of services includes 1,100 test panels. 2,028 pathology tests and 1.561 radiology and cardiology tests.
As on March 31, 2017, DLPL has 189 clinical labs 1,759 patient service centers and 5,021 pickup points. In FY16 & FY17, DLDL collected and processed approximately 26.3 million samples and 29.3 million samples from approximately 12.0 million and 13.3 million patients respectively.
The current stock price is 1057
The current stock price is 1057
Check the company's annual presentation. https://urlzs.com/vzg23
To know about the Company: https://www.youtube.com/watch?v=M4flaRvOEyo
Dr. Lal path labs Stock analysis: https://www.youtube.com/watch?v=ZAa-_Xsn6LM
Future Growth of the company and share price :
DLDP is trading at Rs.1038 and we see a 22 % return on this stock. Immediate positive catalysts are nonexistent but de-rated valuation (low profitability and regulatory risks ) are ignoring:
1) Levers to offset regulatory headwinds;
2) Industry structure improving in favor of large chain
3) Increasing affordability
4) Cost efficiencies
5) Bargaining power
6) Medical Tourism
7) Tertiary care offers growth longevity
8) Fragmented Rs4trn market
Dr. Lal path labs are moat of deep reach, reputation and scale are snowballing in North, Central, East regions. NCE is lesser competitive, large and under-penetrated. This will drive high longevity of DLPL earnings growth outperformance. Regulations are a worry yet DLPL has levers to offset it through itemized pricing and gain from unorganized. Revenue growth would moderate at 14% CAGR secularly, but longevity and low Capex intensity drive high multiples embedded in our DCF drive TP of Rs 1,276/share. Regulations and capital allocation are key catalysts (gain from the unorganized, cheap acquisition of regional players) as well as risks (price cuts offsetting volume growth, expensive acquisition).
Posts
){kind=link}
2 Comments
Hello everyone..Welcome to my free masterclass strategy where i teach experience and inexperience traders the secret behind a successful trade.And how to be profitable in trading I will also teach you how to make a profit of $12,000 USD weekly and how to get back all your lost funds feel free to email me on(brucedavid004@gmail.com) or whataspp number is +22999290178
ReplyDeleteThanks for sharing this very diverse opinion post where each expert has no doubt shared his best knowledge. For more knowledge and information about RT-PCR test Delhi.
ReplyDeleteGreat topic and I am really amazed to read this. It's really good. Search for more on topic Rapid Antigen Test Delhi At Home.
I am happy to read this. This is the kind of knowledge that needs to be given and not random misinformation. Appreciate you for sharing this post. For gaining more knowledge about Health Packages Delhi.
Thank you for your valuable comment